EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Adjunctive Multisensory Passive Immersive Virtual Reality With Synchronized Plantar Tactile Stimulation for Gait and Balance Disorders in Parkinson's Disease: An Exploratory Randomized Controlled Trial

Igor Shirolapov, Sviatoslav Natalevich, Elena Khivintseva, Yuliya Komarova, Natalia Romanchuk, Mariya Sergeeva, Nikolay Popov, Vladimir Kalinin, Alexander Zakharov

European Journal of Neuroscience · 2026-11 · 64 (9)

DOI: 10.1111/ejn.70754 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Postural‐locomotor disorders, particularly freezing of gait and postural instability, are among the most disabling symptoms of advanced Parkinson's disease (PD) and respond only partially to dopaminergic therapy. Evidence for virtual reality (VR) approaches in moderate to severe PD remains limited. This prospective randomized controlled open‐label exploratory trial evaluated the addition of multisensory passive immersive VR with synchronized plantar tactile stimulation to conventional rehabilitation for gait, balance, and freezing disorders in moderate‐to‐severe PD (Hoehn and Yahr Stages 2–4). In the study, 80 PD patients were randomized into an experimental group (EXP, n = 40) receiving standard pharmacotherapy and conventional rehabilitation plus 10 sessions of passive immersive VR with synchronized plantar tactile stimulation and a comparison group (COM, n = 40) receiving standard pharmacotherapy and conventional rehabilitation only. Because the VR sessions were added to an otherwise identical program, the trial evaluates the effect of adding this intervention rather than a VR‐ or tactile‐specific effect. Outcomes were assessed at baseline and after 10 days using the Unified Parkinson's Disease Rating Scale (UPDRS), Berg Balance Scale (BBS), and Freezing of Gait Questionnaire (FoG‐Q). The EXP group showed significant improvements in the UPDRS “Gait” cluster (an eight‐item composite of UPDRS items 2.11, 2.12, 2.13, 3.9, 3.10, 3.11, 3.12, and 3.13, range 0–32; median from 12.5 to 8.0 points, p < 0.001), BBS (from 38.0 to 43.5 points, p < 0.001), and FoG‐Q (from 9.0 to 6.5 points, p < 0.001). A formal group × time analysis confirmed a differential treatment effect for every outcome. For the main outcome, the UPDRS “Gait” cluster, the baseline‐adjusted between‐group difference was −2.48 points (95% CI −3.37 to −1.59; p < 0.001; Hedges' g = 1.16). Large effects also favored the EXP group for the FoG‐Q (−2.14 points, 95% CI −2.62 to −1.66; g = 1.65), the BBS (+2.20 points, 95% CI 1.31 to 3.10; g = 1.06), the UPDRS freezing subscore (items 2.13 + 3.11; −0.89 points, 95% CI −1.13 to −0.66; g = 1.32), and the UPDRS postural subscore (items 3.12 + 3.13; −0.74 points, 95% CI −1.08 to −0.41; g = 0.93). Secondary outcome p ‐values were adjusted for multiple comparisons using the Holm and Benjamini–Hochberg procedures. By contrast, in the COM group, no significant change was observed for freezing of gait ( p = 0.083), and improvements in other outcomes were smaller than in the EXP group. No serious adverse events were recorded. The trial was exploratory, so the effect estimates require confirmation rather than supporting robustness in themselves. Overall, multisensory passive immersive VR with synchronized plantar tactile stimulation was well tolerated and shows preliminary promise as an adjunct to conventional rehabilitation for gait and balance disorders in moderate‐to‐severe PD. Wider clinical implementation requires long‐term multicenter studies with standardized assessment criteria and analysis of long‐term sustainability. These findings support integrating passive VR technologies into personalized neurorehabilitation programs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →